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Abstract: Immunotherapy has changed the paradigm of cancer treatments. In this way, several
combinatorial strategies based on monoclonal antibodies (mAb) such as anti (a)-PD-1 or anti (a)-PD-L1
are often reported to yield promising clinical benefits. However, the pharmacokinetic (PK) behavior
of these mAbs is a critical issue that requires selective analytical techniques. Indeed, few publications
report data on a-PD1/a-PD-L1 exposure and its relationship with therapeutic or toxic effects. In this
regard, preclinical assays allow the time profiles of antibody plasma concentrations to be characterized
rapidly and easily, which may help to increase PK knowledge. In this study, we have developed
and validated two in-house ELISAs to quantify a-PD-1 and a-PD-L1 in plasma collected from
tumor-bearing mice. The linear range for the a-PD-1 assay was 2.5–125 ng/mL and 0.11–3.125 ng/mL
for the a-PD-L1 assay, whereas the intra-and inter-day precision was lower than 20% for both analytes.
The PK characterization revealed a significant decrease in drug exposure after administration of
multiple doses. Plasma half-life for a-PD-1 was slightly shorter (22.3 h) than for a-PD-L1 (46.7 h).
To our knowledge, this is the first reported preclinical ELISA for these immune checkpoint inhibitors,
which is sufficiently robust to be used in different preclinical models. These methods can help to
understand the PK behavior of these antibodies under different scenarios and the relationship with
response, thus guiding the choice of optimal doses in clinical settings.
Keywords: PD-1; PD-L1; ELISA; validation; pharmacokinetics
1. Introduction
Therapeutic monoclonal antibodies (mAb) represent one of the most promising strategies to treat
different types of diseases, including cancer [1]. In this context, mAbs against certain upregulated
molecules in cancer cells and the tumor microenvironment have opened up new mechanisms to achieve
tumor regression [2]. Cancer immunotherapy based on the modulation of the immune system using
certain mAbs has substantially contributed to achieving relevant clinical outcomes [3].
In this regard, immune checkpoints (ICs) such as Programmed Death-1 receptor (PD-1) and its
endogenous ligands, PD-L1 (B7-H1) and PD-L2 (B7-DC), have been shown to be validated targets for
cancer treatments [4]. PD-1, known as CD279, is a type I transmembrane protein belonging to the
CD28 family of immune regulatory receptors, mainly expressed in activated T-cells, which promotes
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their proliferation and self-tolerance [5]. Indeed, expression of this receptor declines as the antigen is
successfully eliminated. On the other hand, PD-L1 (B7-H1), a transmembrane glycoprotein included in
the B7 family of immune regulatory molecules [6], is constitutively expressed on inflammatory-activated
immune cells such as macrophages, T-and B cells, and endothelial and intestinal epithelial cells and is
also inducible in many other cells, particularly cancer cells in the presence of certain pro-inflammatory
stimuli [7].
PD-1/PD-L1 binding promotes the reduction of T-cell proliferation, inducing immune suppressor
cytokine production that leads to lymphocytes apoptosis, anergy, and functional exhaustion, as is
depicted in Figure 1 [5,8]. This mechanism involved in avoiding auto-immunity is responsible for
tumor immune escape. In that sense, the blockade of this PD-1/PD-L1 interaction by specific mAbs
(a-PD-1 or a-PD-L1) has demonstrated tumor eradication and has contributed to the enhancement of
other cancer therapies [9,10].
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, despite their therapeutic eff cts, inter-ind vidual var ability is very high, ranging from
responders to non-responders [12]. This characteristic m kes difficult the establ shment of an adequate
relationship between antibody exposure and efficacy, thereby limiting the administration of adequate
dosing regimens. Thus, characterization of the pharmacokinetic (PK) behavior of these mAbs would
be very useful in guiding individual doses to achieve tumor regression in each patient. At this point,
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the paucity of studies focusing on the PK characterization of IC inhibitors (ICIs) highlights the need to
know more about their behavior in order to help in predicting clinical responses.
Preclinical models have contributed to studying the PK of different mAbs and the impact on
response. Indeed, physiological PK models seem to improve the characterization of drug behavior,
providing the most relevant platform to achieve appropriate human dose escalation [13]. However,
the studies on the biodistribution of these biological agents in animals have been done in many
cases by imaging experiments [14–16], highlighting the need to develop selective and sensitive
analytical techniques to quantify plasma and tissue antibody concentrations accurately. In this way,
the enzyme-linked immunosorbent assay (ELISA) is the most popular analytical assay to measure mAbs
in different biological matrices [17]. To our knowledge, no publications reporting ELISA validation for
these ICIs in preclinical tumor mice models are currently available.
Therefore, this work aims to develop and validate two easy-to-use ELISAs to quantify a-PD-1 and
a-PD-L1 plasma concentrations collected from tumor-bearing mice and determine the PK profiles and
main parameters of these agents.
2. Materials and Methods
2.1. Materials
Recombinant mouse PD-1-Fc Chimera, PD-L1/B7-H1-Fc Chimera Protein, and a-Goat IgG
HRP-conjugated antibody were purchased from R&D Systems® (Minneapolis, MN, USA).
3,3’,5,5’-tetramethylbenzidine (TMB) was obtained from Millipore® (Burlington, MA, USA). Bovine
Serum Albumin (BSA), sulfuric acid, streptavidin-peroxidase, and Tween-20 were obtained from
Sigma Aldrich® (St. Louis, MO, USA). DPBS without calcium and magnesium and fetal bovine serum
(FBS) were purchased from Gibco® (Madrid, Spain). Rat a-mouse-PD-1 mAb (CD279; clone RMP1-14)
and rat a-mouse PD-L1 (B7-H1, clone 10F.9G2) were obtained from BioXCell® (West Lebanon, NH,
USA). The Goat a-Rat IgG, (H+L) antibody, Biotin Conjugated was purchased from Thermo scientific®
(Waltham, MA, USA).
2.2. Methods
2.2.1. ELISA Development and Validation
Matrix Selection
In order to quantify plasma levels of a-PD-1 and a-PD-L1, two different sandwich ELISAs were
developed and validated in our laboratory. To that end, a plasma matrix obtained from C57/B6J
drug-free mice was used to prepare standard samples. Briefly, blood samples were collected in
heparinized-EDTA tubes and centrifuged at 4◦C for 3500 rpm for 15 min to obtain the plasma, which
was kept at −20◦C until use.
The stock solution for ELISAs was prepared using this drug-free plasma diluted 1:150 (v/v.) in
incubation buffer (IB; 0.05% Tween-20, 0.1% BSA in DPBS) obtaining the matrix buffer (MB). This
MB was spiked with different known drug concentrations to prepare the standard samples and the
analytical control, which corresponded to free-drug MB.
Calibration Standard Curves
Two working solutions or stocks, 500 ng/mL for a-PD-1 and 250 ng/mL for a-PD-L1, were freshly
prepared in MB to build the corresponding calibration standard curves.
a-PD-1 ELISA
Figure 2A shows the schematic representation of the developed a-PD-1 ELISA sandwich method.
Briefly, 24 h before performing the assay, a flat-bottomed 96-well Maxisorp microplate (NUNC,
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Thermoscientific, Rochester, NY, USA) was coated with 2 µg/mL of recombinant mouse-PD-1 capture
fusion protein diluted in DPBS and incubated at 4◦C overnight. Afterward, the plate, washed twice
with 200 µL/well of DPBS, was blocked with 200 µL/well of IB for 1 h at room temperature (RT) to
prevent unspecific reactions. Then, the plate was washed five times using 200 µL/well of washing
buffer (0.05% Tween-20, DPBS; WB), and the standards and experimental samples (100 µL/well) were
added and incubated for 2 h at RT. For the labeling, the plate was washed and treated for 1 h with
a secondary goat a-rat IgG antibody (1:20.000, v/v. IB). In order to amplify this signal, a-Goat IgG
HRP-conjugated antibody was added (1:5.000, v/v. IB) and incubated for 1 h at RT.Pharmaceutics 2020, 12, x 5 of 16 
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Figure 2. Schematic representation of the sandwich ELISA developed and validated in the present work.
(A) ELISA to qua tify a-PD-1 in plasma; numbers correspond to the consecutive steps: (1) addition of
secondary goat α-rat IgG, (2) incubation with α-goat IgG HRP-conjugated antibody, (3) incorporation of
TMB substrate, (4) stopping of the reaction with H2SO4. (B) ELISA to detect a-PD-L1 in plasma;numbers
correspond to the different steps of the ELISA: (1) addition of secondary goat α-rat IgG biotin conjugate,
(2) incubation with streptavidin-peroxidase, (3) incorporation of TMB substrate, (4) stopping of the
reaction with H2SO4.
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The plate was washed and revealed with 100 µL/well of TMB for 3 min. This reaction was stopped
by adding 50 µL/well of sulphuric acid (2 N), and the absorbance was read at 450 nm in PowerWave™
XS Microplate Reader from BioTek Instruments, Inc (Winooski, VT, USA).
a-PD-L1 ELISA
The protocol for this ELISA (Figure 2B) was similar to the a-PD-1 ELISA described above. Aliquots
of 2 µg/mL of recombinant mouse-PD-L1 capture fusion protein diluted in DPBS (100 µL/well) were
placed in a flat-bottomed 96-well Maxisorp microplate and incubated in darkness overnight at 4◦C.
After being washed twice with DPBS, wells were blocked with 200 µL/well of IB for 1 h at RT. Then,
samples and standards prepared with MB (100 µL/well) were added and incubated for 2 h at RT.
Immediately after, the plate was washed and incubated with a Goat a-rat IgG antibody (1:100,000, v/v.
in IB) for 1 h at RT, followed by another 1 h incubation with Streptavidin-peroxidase (1:50,000 v/v. in
IB) at RT in darkness. The plate was revealed with 100 µL/well of TMB for 3 min. This reaction was
stopped by adding 50 µL/well of sulphuric acid (2 N), and the absorbance was read at 450 nm.
2.2.2. ELISA Validation
The criteria for the analytical assay validation were performed in accordance with the current
recommendations for bioanalytical methods: linearity, accuracy, precision, and reproducibility [18,19].
Optimization of the Labeling Signal
Several dilutions of the secondary antibody were evaluated to optimize the signal. In the case
of a-PD-1, the a-Goat IgG HRP-conjugated antibody was tested at three dilutions (1:2500, 1:5000,
and 1:10,000), whereas for a-PD-L1, the Goat a-rat IgG antibody was assayed at two dilution levels
(1:75,000 and 1:100,000).
Linear Range
Several standard samples were prepared to establish and analyze the linear range of calibration
curves. The stock solutions, 500 ng/mL for a-PD-1 and 250 ng/mL for a-PD-L1, were used to prepare serials
of drug concentrations in MB for the standard curves. The parameters, slope, and intercept corresponding
to the linear regression curve (y= ax+b; where y, represents the signal and x, the independent variable or
antibody concentration) were calculated for each assay and statistically analyzed according to the intra-
and inter-day variability [19,20]. The correlation was established by r2 ≥ 0.98.
Determination of the Limits of Quantification and Detection
The sensitivity of the assay is often described by the Limit Of Quantification (LOQ), which is the
lowest point at which the analyte or therapeutic molecule can be accurately measured. The Limit of
Detection (LOD) was also determined, being considered as the lowest quantity of a substance that can
be distinguished from the absence of that substance (a blank value). To establish the corresponding
values for LOQ and LOD, ten replicates of controls or MB samples were analyzed. The following
formulas were applied to calculate both values:
LOQ = (mean/SD) × 10 (1)
LOD = (mean/SD) × 3.3 (2)
where mean corresponds to the average value of control MB samples and SD to their standard
deviation [21].
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Precision and Accuracy
The precision parameter accounts for the repeatability (intra-day or within-day variability) and
reproducibility (inter-day or between-day variability). To determine the repeatability, three specific
concentration levels covering the linear range were selected for both assays: 62.5, 31.3, and 3.9 ng/mL
for a-PD-1 and 3.125, 0.781, and 0.195 ng/mL for a-PD-L1.
Each sample, prepared in triplicate, was analyzed on the same day and on three different days.
The first analysis determined the assay precision referred to the intra-day variability and the following
analyses were for the inter-day variability. In both cases, the value was calculated by the following
formula:
Precision (%CV) = (SD/Mean) × 100 (3)
Accuracy, expressing the closeness between the real concentration and the measured value
according to the developed assay, was performed and calculated with this formula:
Accuracy (% Mean bias) = (Observed concentration/Theoretical concentration) × 100 (4)
Therefore, the imprecision of the determination was:
Imprecision = Accuracy − 100 (5)
According to the guidelines, precision should be < 20%, and accuracy should be within ± 20% [18,19].
Stability and Plate Drift
The stability ofsamples was determined using three concentration levels of a-PD-1,(62.5, 31.3,
and 3.9 ng/mL) and of a-PD-L1 (3.125, 0.781, and 0.195 ng/mL).These samples were analyzed just after
preparation, kept at 4 ◦C and analyzed again one month later, to evaluate the impact of storage.
In addition, the plate drift variability was also analyzed to establish whether the time elapsed
during plate-well preparation (samples plus reagents) couldaffect the results.To that end, some samples
were added in the first-row wells, and the same samples were placed in the last row wells after
completing the plate. The absorbance was statistically compared to determine possible differences.
2.2.3. a-PD-1 and a-PD-L1 Pharmacokinetics
In vivo experiments were performed according to the European animal care regulations
andprotocols approved by the Ethics Committee of the University of Navarra (Reference number
023/17, aprobbed on 6 April 2017 and reference number protocol 129/16, aprobbed on 15 November
2016). Female C57BL/6 mice (5-week old, weighing approximately 20 g supplied by Harlan, Barcelona,
Spain) were housed in plastic cages under standard and sterile conditions, 25 ◦C, 50% relative humidity,
12 h dark/light, with water and food ad libitum. Two tumor cell lines, TC-1/A9 and B16-OVA, were used
for this study. ICIs’ plasma levels were quantified with the previously validated ELISAs and analyzed
by a linear regression approach, using log-transformed data and considering a biphasic disposition.
The time profiles of the plasma concentrations for the two antibodies were built using the average
value corresponding to the three mice used at each time point (see Sections 2.2.3.1 and 2.2.3.2). The area
under the plasma concentration versus time curve (AUC0−∞) was calculated by the linear trapezoidal
method. For the extrapolated area, AUC72h−∞, the last concentration C72h was divided by the slope (k)
obtained from the terminal portion of the curve that determines the rate of drug decline:
[AUC]∞72h = C72h/k (6)
other parameters such as half-life, clearance (Cl), and volume of distribution (Vd) were estimated
according to the equations t1/2 =0.693/k, CL = Dose/AUC0−∞ and Vd = Cl /k, respectively.
The plots were built in RStudio (version3.4.3) using the ggplot2 package.
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2.2.3.1. Characterization of a-PD-1 Pharmacokinetics
A total of nine C57/B6J female mice were inoculatedwith TC-1/A9, a cervix carcinoma murine cell
line, kindly provided by Dr. Pedro Berraondo (CIMA, Pamplona, Spain). Cells, maintained in standard
culture conditions (5% CO2 and 37 ◦C), were grown in RPMI 1640 with GlutaMAX supplemented
with FBS (10%(v/v)), Penicillin/Streptomycin(1%(v/v)), Geneticin (0.4 mg/mL), and 2-mercaptoethanol
(0.05 mM). Mycoplasma was regularly tested for with a luminescence assay (LONZA, Basel, Switzerland).
Tumor cells (1 × 105 cells/100 µL PBS) were subcutaneously inoculated into the right flank of
animals. One week later, when the average tumor diameter was approximately 5 mm, mice were
treated (n = 9), receiving, intravenously, 100 µL of drug solution via tail vein and four administrations
of 200 µg/mouse a-PD-1 dose every 72 h, as shown in Figure 3A. 100 µL blood samples were collected
into heparin tubes by facial puncture at 10, 30 min and 1, 3, 8, 24, and 72 h after the first and fourth
dose administration. To that end, animals were randomly divided into three subgroups (n = 3) to
obtain a maximum of three blood samples per animal during each cycle of treatment. All samples
were centrifuged at 3500 rpm for 15 min at 4 ◦C, and plasma was kept at −20 ◦C until analysis. These
samples were diluted 1:150, as the calibration curves, followed by another 1:2 dilution, in the case of
the three first time points.Pharmaceutics 2020, 12, x 8 of 16 
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(A) a-PD-1 was intravenously (iv) administered to TC-1 tumor-bearing mice; (B) a-PD-L1 was iv injected
to B16-OVA tumor-bearing mice.
2.2.3.2. Characterization of a-PD-L1 in an In Vivo Model
The B16-OVA melanoma murine cell line, kindly provided by Dr. Sandra Hervás-Stubbs
(CIMA, Pamplona, Spain), was used to establish the in vivo tumor model. Cells, maintained in
standard culture conditions, were grown in RPMI 1640 with GlutaMAX supplemented with FBS
(10%(v/v)), Penicillin/Streptamycin(1%(v/v)), Geneticin (0.4 mg/mL), 2-mercaptoethanol (0.05 mM),
and Hepes (20 mM). Geneticin was added to culture medium during the two first passages to assure
OVA expression.
Tumor cells at a density of 5 × 105 cells/100µL PBS were subcutaneously injected into the right
flank of the animal. One week later, when tumors reached a diameter of approximately 5 mm, mice
(n = 9) were intravenously injected with 100 µL of drug solution via the tail vein. The treatment
consisted of four administrations of 100 µg/mouse of a-PD-L1 every 72 h (Figure 3B).
Pharmaceutics 2020, 12, 595 8 of 16
Animals, divided into three subgroups (n = 3) were randomly assigned to the different time
points for a maximum of three blood sample collections in each cycle of treatment per mouse. Blood
samples (100 µL) were collected by facial puncture at 10, 30 min and 1, 3, 8, 24, and 72 h after first and
fourth dose administration into heparin tubes. Plasma samples were kept at −20 ◦C until analysis.
These plasma samples were diluted 1:150 followed by an extra 1:20 dilution for the first dose and
time points.
2.2.4. Statistical Analysis
All data were expressed as mean ± SD and coefficient of variation (CV) using GraphPad Prism 6
(GraphPad Software, San Diego, CA, USA). The Student t-test or U-Mann-Whitney, depending on the
number of data per group, were applied for statistical comparison of the two groups. The significance
level was set at 0.05.
3. Results
3.1. ELISA Validation
3.1.1. Optimization of the Secondary Antibody
The optimization of the secondary antibody dilution was the first issue to tackle. Several curves,
as shown in Figure 4, were built using different antibody dilutions in order to find the most adequate
slope for the relationship between ICI concentration and analytical signal. The dilution selected for the
a-PD-1 assay was 1:5000 and for a-PD-L1 was 1:100,000, as both provided a linear relationship. For the
other conditions 1:2500 (a-PD-L1) and 1:75,000 (a-PD-1), a rapid saturation of the signal was found,
thus posing serious difficulties for antibody quantification.
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3.1.2. Linearity
The linear range for a-PD-1 was established between 125 and 2.5 ng/mL. However, for a-PD-L1,
this range was narrower, between 3.125 and 0.10 ng/mL .Several standard curves were prepared in
these ranges, and the linearity was determined by the correlation parameter r2, which turned out to be
≥ 0.98, as is represented in Figure 5. In addition, Table 1 lists the individual standard curve equations
obtained in the linear range for both antibodies, together with the corresponding correlation value,
demonstrating the linear relationship between antibody concentrations and the absorbance signal.
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Table 1. Regression curves and r2 calculated for each calibration curve and for the average curve.
PD-1 PD-L1
Curve Equation r2 Curve Equation r2
y = 0.005645x +0.1341 0.99 y = 0.1403x + 0.10950 0.99
y = 0.003423x + 0.1359 0.99 y = 0.1386x + 0.09234 0.99
y = 0.003899x + 0.1414 0.99 y = 0.1473x + 0.09648 0.99
y = 0.004170x + 0.1156 0.99 y = 0.1382x + 0.08988 0.99
y = 0.004084x + 0.1192 0.98 y = 0.1476x + 0.11510 0.99
y = 0.004636x + 0.1503 0.99 y = 0.1551x +0.10730 0.99
Average curve Average curve
y = 0.004408x + 0.1367 0.99 y = 0.1419x + 0.09598 0.99
In addition, Table 2 reports the slopes and intercepts for each standard curve prepared for both
antibodies, a-PD-1 and a-PD-L1 respectively. The CV calculated for these parameters was in all cases
< 20%, suggesting a low variability associated with the ELISA. Non-statistical differences across the
parameters estimated for the standard curves corresponding to each ICI were found.
Table 2. Interval for slope and intercept for each standard curve, with the linearity range. Data were
calculated using six different standard curves for each antibody.
Antibodies
Slope Intercept Linear Range (ng/mL)
CI (95%) (ng/mL) CV CI (95%) (ng/mL) CV
a-PD-1 0.00405–0.0047 10.89% 0.1195–0.1539 9.95% 125–2.5
a-PD-L1 0.1347–0.1492 12.34% 0.08672–0.105 10.20% 3.125–0.11
CI: confidence interval.
3.1.3. LOQ and LOD
LOD for a-PD-1 and a-PD-L1 were established at 0.12 ng/mL and 0.03 ng/mL respectively, whereas
LOQ was determined as 2.5 ng/mL for a-PD-1 and 0.11 ng/mL for a-PD-L1.
3.1.4. Precision and Accuracy
Inter-and intra-day accuracy and imprecision for both ELISAs are reported in Table 3. The selected
drug concentrations were in the range of high, medium, and low, according to the linear range.
All samples were prepared following the previously described methodology. For precision, the intra-
and inter-day bias ranged from 2.91 to 9.68% and 5.92 to 9.15%, respectively, in the case of a-PD-1.
In the case of a-PD-L1, the range was between 6.56 and 5.31% for intra-day and between 7.75 and 7.30%
for inter-day as is reported below.
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Table 3. Statistical analysis of three different mAb concentrations to determine the precision of the (A)
a-PD-1 ELISA; (B) a-PD-L1 ELISA.
(A)
Intra-Day Variability Inter-Day Variability
62.5 ng/mL 15.62 ng/mL 3.9 ng/mL 62.5 ng/mL 15.62 ng/mL 3.9 ng/mL
Average 64.04 15.85 4.06 62.85 16.27 3.82
SD 1.24 2.32 0.52 2.74 2.22 0.53
CV 1.94% 14.66% 12.79% 4.36% 13.64% 13.85%
Imprecision 2.47% 1.51% 4.29% 0.57% 4.19% −1.90%
(B)
Intra-Day Variability Inter-Day Variability
3.12 ng/mL 0.78 ng/mL 0.19 ng/mL 3.12 ng/mL 0.78 ng/mL 0.19 ng/mL
Average 2.721 0.90 0.19 2.95 0.90 0.21
SD 0.405 0.04 0.02 0.184 0.05 0.03
CV 14.87% 4.87% 9.98% 6.21% 5.36% 16.54%
Imprecision −12.93% 15.46% −4.63% −5.33% 15.84% 7.17%
The variability or CV associated with the different antibody concentrations was < 10%, although
for the lowest a-PD-1 plasma concentration, there was a tendency for it to be higher, but this is not
expected to have any particular impact on further results. In addition, the imprecision of the assays
was < 20%.
In order to evaluate the impact that the dilution of the highest concentration may have on
the results from both assays, the accuracy of serial dilutions prepared with the same sample was
determined. Results in Table 4 show that the dispersion was < 10%. This finding, together with
imprecision percentages, supports the notion that the ELISA procedures were sufficiently accurate to
be applied in in vivoplasma samples.
Table 4. Impact on the accuracy and imprecision of the dilution of highest antibody concentrations.
Antibodies
Dilutions
1:1 1:2 1:4 1:8
a-PD-1 (62.5 ng/mL) 58.71 ± 0.98 63.83 ± 13.86 64.04 ± 1.86 61.93 ± 4.66
Imprecision 6.06% 2.13% 2.46% 0.91%
a-PD-L1 (3.25 ng/mL) 3.14 ± 0.48 3.25 ± 0.51 3.39 ± 0.18 3.26 ± 1.06
Imprecision 3.38% 0.00% 4.31% 0.31%
3.1.5. Stability and Plate Drift
The impact of plate drift was evaluated using the highest plasma concentration of a-PD-1
(62.5 ng/mL) and a-PD-L1 (3.125 ng/mL), respectively. Aliquots of these samples were placed in the
first and the last row. Results for a-PD-1 did not differ statistically between the first and the last
wells, which were totally comparable (61.94 ± 6.9 ng/mL vs. 58.63 ± 5.49 ng/mL). This finding was
similar to a-PD-L1, where the concentration in the first and the last rows, 3.383 ± 0.81 ng/mL vs.
3.469 ± 0.46 ng/mL, were almost exactly the same.
On the other hand, since in vivo plasma samples are often kept on ice during hours before the
performance of the analytical assay, the antibody stability in this matrix was evaluated. Several plasma
samples using high, medium, and low concentrations of the two antibodies were prepared. Table 5
shows the results for these assays. No statistically significant differences were found in any case,
thus supporting adequate stability during at least one month.
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Table 5. Stability of antibody in plasma samples kept at 4 ◦C for one month. (ns: non-statistically
significant differences).
a-PD-1 a-PD-L1
ng/mL Fresh Sample Day 30 p ng/mL Fresh Sample Day 30 p
62.5 64.18 ± 8.38 61.81 ± 5.10 ns 3.125 3.53 ± 0.27 3.82 ± 0.44 ns
15.6 17.05 ± 3.65 16.69 ± 2.53 ns 0.781 0.90 ± 0.16 0.81 ± 0.03 ns
3.9 3.258 ± 1.25 3.464 ± 1.75 ns 0.195 0.189 ± 0.01 0.24 ± 0.04 ns
3.2. InVivo Characterization of Plasma Immune Checkpoint Inhibitor Levels
3.2.1. a-PD-1 Plasma Time Course Profile
Blood samples were collected at different time points between 10 min and 72 h after dose
administration. Figure 6, left panel, shows the time profile of a-PD-1 plasma concentrations after the
first iv administration to TC-1 tumor-bearing mice.Pharmaceutics 2020, 12, x 12 of 16 
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Figure 6. (a) Time course profile of a-PD-1 plasma concentrations collected from tumor-bearing ice at
different time points after receiving the first dose (n = 3/time point). Experimental data are represented
by points and the solid line corresponds to the mean (left panel). (b) Box plots represent the plasma
concentrations at 10, 30, and 60 min after the first and fourth administrations; symbols show the
observed data (right panel).
The half-life calculated by a non-compartmental approach was approximately 25 h, with a
drug exposure expressed as AUC0−∞ of 2427.35 µg·h/mL (Table 6). The right panel in Figure 6
shows a comparison between plasma concentrations at 10, 30, and 60 min after the 1st and the 4th
dose administration. An important change in the exposure to the drug achieved after repeated
dose was observed. Indeed, the mean plasma levels at 10 min after the first dose was double
(128.01 ± 11.52 µg/mL) compared to after the fourth dose (63.43 ± 4.59 µg/mL) (p < 0.05). Note that for
the fourth dose, most of the plasma concentration values were below the limit of quantification.
Table 6. Drug exposure expressed as AUC0−∞ after first dose administration and the parameters, t1/2,
Cl, and Vd, calculated by linear regression.
AUC0−∞ (µg·h/mL) t1/2(h) Cl (mL/h) Vd (mL)
2427.35 22.3 0.0823 2.5
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3.2.2. a-PD-L1 Plasma Time Profile
Figure 7 shows the time course profile of a-PD-L1 plasma levels quantified in B16-OVA
tumor-bearing mice after receiving 100 µg of mAb/mouse iv. The treatment consisted of four
doses administered every 3 days. Plasma levels were quantified after the first and fourth doses to
determine possible changes during each cycle. In this case, the half-life calculated also by a linear
regression was 46.7 h, slightly longer than for a-PD-1, although more data would be needed to increase
the robustness of these results (Table 7). In addition, as occurred with a-PD-1, data after the fourth
dose showed a reduction in antibody plasma levels at 10 min (19.13 ± 4.19 mg/L) up to 3.5 times in
comparison with the first dose (66.99 ± 17.4 mg/L) (p < 0.001), as is observed in the right panel of
Figure 7.Pharmaceutics 2020, 12, x 13 of 16 
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Table 7. Drug exposure expressed as AUC0−∞ after first dose administration and the parameters, t1/2,
Cl, and Vd calculated by linear regression.
AUC0−∞ (µg·h/mL) t1/2 (h) Cl (mL/h) Vd (mL)
1996.42 46.7 0.050 3.3
Drug exposure in this case was lower than for a-PD-1, because the dose administered to mice was
100 µg instead of the 200 µg used for a-PD-1, and due to the high variability, it was difficult to confirm
a correlation between dose and drug-exposure.
4. Discussion
Immune checkpoint inhibitors currently represent the most promising therapeutic agents
in oncology. However, unfortunately, these mAbs are associated with a high inter-individual
variability [12]. To investigate these differences in detail, a particular effort in developing animal
models and analytical assaysis required. In the case of therapeutic antibodies, ELISA is one of the most
commonly used techniques, due to its specificity and precision [17].
Although the methodology applied for both murine antibodies was similar, they showed a very
different linear-range: 125–2.5 ng/mL for a-PD-1 and 3.125–0.11 ng/mL for a-PD-L1. This might be
explained by the difference in the antibody isotype (IgG2a and IgG2b, respectively) or their affinity
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for the recombinant protein used to cover the ELISA plates. Indeed, in the a-PD-1 ELISA, unlike the
a-PD-L1, an additional step including two secondary antibodies was necessary to properly amplify the
signal. Even with this extra step, the slope for the a-PD-1 assay proved to be 30 times lower than for
the a-PD-L1, suggesting a lower sensitivity. Nevertheless, both assays were validated and shown to be
sufficiently robust to evaluatein vivo plasma samples.
Thus, we have characterized the time-course profiles of a-PD-L1 and a-PD-1 plasma concentrations
after repeated iv administrations to mice. Note that we have used tumor-bearing mice to evaluate
the PK behavior of antibodies in contrast to other studies in which mice were tumor-free [22,23].
Furthermore, few papers are available in the literature regarding the PK characterization of a-PD-1
and a-PD-L1. These characterizations are based mainly on imaging methods and even radioactivity
levels [14,24]. In the studies on a-PD-1 or a-PD-L1 quantification in different matrices, most of the data
correspond to human or primate serum samples with clear differences in the results across ELISA
data [19,25–27].
Indeed, for a-PD-1 ELISA, there is no clear consensus on LOQ values for human mAbs. For example,
Pluim et al., have reported 2 ng/mL, a very similar cipher to the result found here (2.5 ng/mL) [25],
while other authors such as Fu et al. [26] or Puszkiel et al. [19] have reported 19.531 ng/mL and 5 µg/mL,
respectively. Note that there are some important differences in the procedures: (i) Pluim and co-workers
used a-PD-1 to cover the plates, whereas Puszkieland co-workers used a human recombinant PD-1/Fc;
(ii) Pluim et al., found important serum interference in the assay, while this was negligible in the
assay reported by Puszkiel et al.; and finally, (iii) Pluim and co-workers used luminescence for the
quantification in contrast to the UV absorbance used by Puszkiel et al., No detailed information about
the methodology used by Fu et al., is reported, making any comparison with the previous authors
difficult. In any case, our assay methodology is closer to Puszkiel’s work, but the differences in the
a-PD-1 antibody and the recombinant protein might explain the discrepancy in the parameters.
On the other hand, few papers in the literature provide information about a-PD-L1 plasma
level quantification by ELISA. In that sense, Deng and co-workers have reported two quantitative
analytical techniques to measure two new a-PD-L1 molecules [27]. These authors obtaineda linear
range, 0.391–25 ng/mL, larger than the one found in this work, using a dilution factor of 1:20 for
mouse serum samples. However, although the lowest concentration was 0.391 ng/mL, the LOQ was
established at 7.8 ng/mL, higher than 0.11 ng/mL found here; in contrast, the intra- and inter-assay
precision were very similar, even when Deng and co-workers used human proteins, which differ from
those used in this work, a recombinant mouse-PD-L1 chimerato capture a-PD-L1 rat antibody.
Therefore, the methodology as well as the proteins chosen to detect and quantify a-PD-1/a-PD-L1
can influence the results. In any case, the ELISAs developed in the present work were in line with the
validation parameters and results found in the literature.
Regarding in vivo ELISAs application, the PK behavior of these two antibodies was quite similar.
Thus, the volume of distribution for both molecules was similar reflecting the interstitial and vascular
volume, as is reported for this type of therapeutic agent. Regarding mAb clearance, Deng et al.,
have reported 0.0483 mL/h for a 1 mg/kg dose, similar to the value found in this work for a-PD-L1
at 5 mg/kg [27]. In the case of the terminal half-life, both mAbs displayed values shorter than two
days but longer than those reported by Deng. Note that these authors studied the PK of a-PD-L1 in
BALB/c tumor-free mice, and non-interindividual variability was graphically observed. A greater
amount of data would be desirable to better determine mAb PK characterization in blood, as well as
in other tissues for biodistribution. However, the validated analytical assays presented here provide
valuable information, supporting the variability observed in animals that are in line with that found in
patients and, more importantly, to understand the relationship between drug exposure and therapeutic
effects. In this way, the evaluation of the fourth dose has demonstrated a reduction in the exposure
to these antibodies. There are several explanations for this lower exposure after repeated doses
such as an immunogenic effect or a target-mediated drug disposition. Both mechanisms have been
reported for many biological agents affecting the PK behavior in a serious manner such as accelerating
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plasma clearance [28,29]. This finding may support the low efficacy that these antibodies trigger in
monotherapy and the high inter-individual variability, which is also found in patients [12]. In fact,
our group already tested the antitumoral effect in monotherapy of both ICIs, where the effect was
scarce (see supplementary Figure S1A,B).
Thus, the understanding of the relationship between drug exposure and response for a therapeutic
agent in preclinical models might help establish optimal dose regimens in patients. These models
represent an interesting translational platform to explore dose regimens and effects under different
scenarios [13,30].
In conclusion, in this study, we have developed and validated two ELISAs to determine a-PD-1
and a-PD-L1 plasma levels in tumor-bearing mice. These assays have allowed the PK profiles for both
ICIs to be characterized after multiple dosing and provide a basis for applying this methodology to
explore ICI levels in other matrices.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/6/595/s1,
Figure S1: Antitumor effect of a-PD-1 and a-PD-L1.
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